Pharmaceutical drug prices and trends for TOUJEO MAX SOLOSTR

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
TOUJEO MAX SOLOSTR 300 UNIT/ML	00024-5871-02	91.25793	ML	2026-07-22
TOUJEO MAX SOLOSTR 300 UNIT/ML	00024-5871-02	91.26714	ML	2026-06-17
TOUJEO MAX SOLOSTR 300 UNIT/ML	00024-5871-02	91.27065	ML	2026-05-20
TOUJEO MAX SOLOSTR 300 UNIT/ML	00024-5871-02	91.27709	ML	2026-04-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: July 13, 2026

TOUJEO MAX SOLOSTR (insulin glargine) Market Analysis and Price Projections: Coverage, Competitors, Payer Dynamics, and Exclusivity Timing

TOUJEO MAX SOLOSTAR (insulin glargine) is positioned as a high-dose, fixed-volume basal insulin within the insulin glargine franchise, with pricing and utilization shaped by (1) Lantus/Basaglar/Toujeo competitive substitution and (2) payer step-therapy that increasingly favors lower net-cost insulin products. Near-term price trajectory is driven less by the launch cycle for Toujeo MAX and more by insurer contracting pressure across basal insulin, particularly in the insulin glargine and ultra–long-acting segments.

What is TOUJEO MAX SOLOSTAR and how is it marketed versus other insulin glargine products?

Answer: TOUJEO MAX SOLOSTAR is an insulin glargine U-300 product in a higher-dose pen configuration, marketed as a basal insulin for adults with diabetes. It competes within the insulin glargine class against LANTUS (insulin glargine U-100), BASAGLAR (insulin glargine U-100 biosimilar), and other basal insulins that increasingly capture formulary share via rebate levels and clinical differentiation narratives.

Product scope and dosing form

Drug class: Long-acting basal insulin
Active ingredient: Insulin glargine
Presentation: Pre-filled pen, U-300 (Toujeo portfolio)
Portfolio relationship: Toujeo MAX SOLOSTAR is part of Sanofi’s Toujeo (insulin glargine U-300) line, which includes standard Toujeo pens in addition to the MAX format.

Where Toujeo MAX sits in payer decision trees

In formulary design, basal insulin coverage typically depends on:
- tier placement (preferred vs non-preferred)
- prior authorization triggers (insulin-naïve vs switching)
- step therapy requirements among glargine and other basal agents
- expected “net” cost after rebates, not list price
U-300 basal insulin products have periodic utilization gains where:
- payers price them competitively relative to U-100 glargine and biosimilar baselines
- member savings from reduced dosing or improved glycemic stability fit payer endpoints

What is the current FDA status of TOUJEO MAX SOLOSTAR and how does it affect exclusivity?

Answer: Exclusivity and patent timelines matter for biosimilar or generic entry risk, but practical exclusivity for insulin glargine is governed by patent estates tied to U-300 formulation, pen delivery, and manufacturing, while clinical access is governed by contracting and interchangeability policies.

FDA regulatory posture (what drives competition)

Basal insulin market competition is affected by:
- whether payers treat the product as interchangeable for step therapy
- whether biosimilar substitution is allowed at the pharmacy
- whether plan benefit design routes patients to lower-cost insulin products through co-pay leverage

Key market implication

Even if formal patent exclusivity creates legal barriers for specific protected claims, payer contracting can still shift utilization among competing basal insulins with similar therapeutic effect, which drives real-world share changes faster than litigation outcomes.

How many patents protect TOUJEO MAX SOLOSTAR and what patent types matter most for generic or biosimilar risk?

Answer: A complete “how many” count requires a jurisdiction-specific review of the listed Orange Book patents and associated regulatory exclusivity records; without access to the relevant Orange Book entry set for Toujeo MAX SOLOSTAR in this session, a defensible count cannot be produced.

Patent estate categories that typically matter in basal insulin

Formulation patents: concentration, excipient system, stability
Device/pen patents: dosing mechanism, dose setting accuracy, injection flow
Manufacturing method patents: purification, aggregation control, sterilization, fill-finish
Method-of-use patents: dosing regimens, titration protocols, patient populations
Polymorph/particle-related patents: stability and aggregation control concepts

Practical “risk lens” for Toujeo MAX

For basal insulins, competition often arrives via:
- biosimilar insulin glargine programs (where legally permitted)
- switching to alternative basal insulins regardless of insulin glargine patent timelines
- payer-driven substitution within the formulary rather than a single legal “entry event”

When does TOUJEO MAX SOLOSTAR lose exclusivity and when does legal risk peak?

Answer: A defensible exclusivity-loss timeline requires the specific patent expiration dates and regulatory exclusivity records for Toujeo MAX SOLOSTAR. This session does not include the required Orange Book and patent-number dataset.

What typically creates the “risk peak” in this class

expiration of core drug substance claims
expiration of U-300-specific formulation or manufacturing claims
expiration of device/pen claims that affect “could launch lookalike” barriers
resolution of Paragraph IV-style challenges (if any) for relevant patent frameworks

Market forecasting implication

For insulin glargine products, market share risk often begins before legal expiry due to:

aggressive contracting for competitors
switching protocols that reduce use of premium-branded basal insulins
biosimilar pipeline timelines that influence payer negotiations

How strong is the patent estate for TOUJEO MAX SOLOSTAR compared with LANTUS and BASAGLAR?

Answer: A head-to-head strength comparison requires mapped patent lists and expiration schedules for Toujeo MAX, Lantus, and Basaglar in the relevant jurisdictions, plus claim-by-claim scope. This cannot be completed accurately without the underlying patent datasets.

What a strength comparison usually turns on

overlap in protected concepts between Toujeo MAX and insulin glargine U-100 products
U-300-specific formulation and device claim density
whether protected claims are narrow (product-specific) or broad (covering concentration-independent embodiments)
prosecution history and claim construction risks in litigation

What is the competitive landscape for TOUJEO MAX SOLOSTAR: who are the main payer substitutes?

Answer: The competitive set is led by insulin glargine U-100 (LANTUS and BASAGLAR) and broader basal insulin competitors that form payer step-therapy options based on net cost and formulary position. U-300 Toujeo products compete on clinical profile and dosing convenience while payers compete primarily on rebate economics.

Competitive classes that constrain Toujeo MAX utilization

insulin glargine U-100 (brand and biosimilar)
other long-acting insulins (class-level substitution)
combination strategies and regimen preferences (where basal insulin is bundled with other diabetes management)
pharmacy benefit design levers:
- preferential tiers
- quantity limits
- step therapy for insulin-naïve patients
- copay support eligibility constraints

Forecast impact

In many US plans, utilization shift follows:

formulary tier changes
rebate-driven net price differences
changes in prior authorization criteria for “preferred” products

What price changes are expected for TOUJEO MAX SOLOSTAR: list price, net price, and ASP drivers?

Answer: A concrete price projection requires baseline pricing and trailing ASP and discount/rebate curves for Toujeo MAX, plus plan-level net pricing. This session does not provide the underlying financial time series. Without that dataset, any specific numerical projection would not be grounded.

What actually moves Toujeo MAX price in practice

list price resets driven by manufacturer pricing strategy
gross-to-net mechanics:
- rebates to PBMs and plans
- provider incentives
- buy-and-bill versus pharmacy fulfillment effects
formulary position:
- preferred status usually correlates with higher net rebates
- non-preferred status can reduce volume but sometimes maintains contractual margins through rebates
competitive price walls established by:
- biosimilar entry economics
- competitor contracting aggression in basal insulin classes

Forecast framing that is decision-grade

For business planning, Toujeo MAX pricing forecasts should be modeled as net price outcomes conditioned on:

expected formulary tiering
rebate rate changes tied to utilization share
competitor net-cost pressure scenarios
changes in member cost-sharing that affect demand elasticity

How does TOUJEO MAX SOLOSTAR pricing compare with LANTUS and BASAGLAR?

Answer: A quantified comparison requires product-level pricing (WAC, AWP, ASP) and net pricing or rebate-rate data across the same time period. This session does not contain those figures, so a defensible numeric comparison cannot be produced.

Qualitative pricing dynamics

biosimilar competition tends to compress net prices for the reference molecule class
branded differentiated basal insulin formats can hold net pricing power when payers accept higher unit costs for perceived dosing or clinical advantages
net price often converges toward the cheapest “acceptable” basal insulin in each formulary tier structure

What generic or biosimilar entry risks exist for TOUJEO MAX SOLOSTAR?

Answer: Biosimilar or interchangeable insulin glargine entrants are the primary pathway for insulin glargine market disruption, but the specific entry risk for Toujeo MAX depends on the relevant patent landscape tied to U-300 and device/formulation claims.

Entry pathways to watch (conceptual)

biosimilar candidates targeting insulin glargine originator claims
challenges that attack composition/formulation or manufacturing claims
device-specific design-around that could trigger additional litigation

Market outcome

Even where legal barriers delay entry, competitive pressure can still increase via:

payer switching protocols
competitor contracting that reduces Toujeo MAX demand
expanded patient access to lower-cost basal insulin products

What patent litigation or settlement affects TOUJEO MAX SOLOSTAR market access?

Answer: Litigation and settlements must be mapped to specific patent numbers and case captions. This session does not include those litigation records.

How litigation changes pricing and contracting

settlements can:
- fix launch timing
- constrain design-around strategies
- allow payers to plan rebate strategy without near-term biosimilar displacement risk
adverse court outcomes can:
- accelerate competition
- trigger rapid formulary re-contracting by PBMs

What is the fastest pathway for a generic-like or biosimilar disruption in basal insulin markets?

Answer: In insulin glargine basal insulin markets, the fastest “disruption” frequently comes from payer contracting and formulary substitution rather than a single legal entry date, especially when biosimilar economics shift plan economics quickly.

Practical “launch scenario” for forecasters

scenario A: legal barrier holds but payer reduces preferred positioning
scenario B: a competitor wins preferred placement through net-cost concessions
scenario C: biosimilar entry plus favorable contracting causes rapid volume share shift
scenario D: device or formulation differentiation sustains unit economics despite substitution

How much revenue exposure does Toujeo MAX face from basal insulin substitution?

Answer: A revenue exposure quantification requires:

current revenue share or unit share by segment
plan penetration and tier status
historical switching rates and sensitivity to net price changes This session contains no revenue or utilization inputs, so an exposure estimate cannot be produced.

Revenue exposure drivers

penetration of Toujeo MAX vs other Toujeo SKUs
share of insulin glargine beneficiaries on U-300 vs U-100
payer concentration and negotiation leverage
patient out-of-pocket dynamics affecting adherence

Key takeaways for decision makers

Pricing power is primarily net-price driven in basal insulin markets, with contracting and formulary position often outweighing exclusivity on a quarter-to-quarter basis.
Toujeo MAX faces substitution pressure from insulin glargine U-100 brands and biosimilars via payer step therapy and preferential tiering.
A numeric price projection requires dataset inputs (ASP/WAC/AWP, rebate rates, and tier/plan penetration) that are not available in this session, so credible projections cannot be stated as numbers here.
Legal and patent timelines influence longer-horizon risk, but market displacement can start earlier through payer contracting dynamics.

FAQs

1) What factors determine Toujeo MAX net price in US commercial and Medicare Part D?

Net price is determined by PBM and payer rebates, formulary tier placement, prior authorization requirements, and member cost-sharing design, all of which determine realized discounts versus list-based measures.

2) Does Toujeo MAX pricing track WAC or does it move independently?

In practice, net price can move independently of list price due to rebate renegotiations, formulary re-tiering, and competitor contract changes.

3) What drives switching from insulin glargine U-300 to U-100 biosimilars?

Switching is driven by plan economics and access rules, including step therapy criteria, preferred tier selection, and quantity or PA policies that lower the out-of-pocket barrier to lower-cost alternatives.

4) How does pen format influence payer decisions for Toujeo MAX?

Pen delivery convenience can support prescriber and patient preference, but payer placement ultimately depends on net cost, PA criteria, and limits that affect pharmacy fill behavior.

5) What is the most likely timing pattern for basal insulin price declines?

Price declines often occur as competing net-cost offers take effect during contracting cycles, with sharper adjustments following major formulary moves or competitor launches rather than on a single patent expiry date.

References (APA)

FDA. Drug products, biologics, and medical devices. https://www.fda.gov/drugs
FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/